RPS Awarded DHS Contract to Develop Rapid Diagnostic Tests

Agency Recognizes RPS Technology as Critical to U.S. Bio-Preparedness

SARASOTA, Fla., May 2, 2012 /PRNewswire-USNewswire/ -- Rapid Pathogen Screening, Inc. (RPS®) – an emerging developer of point-of-care diagnostic tests – announced a contract award by the U.S. Department of Homeland Security (DHS) Chemical and Biological Defense Division, to develop and manufacture a rapid, point-of-care diagnostic test to advance U.S. government efforts to aid in diagnosis in the unfortunate incident of a biological attack or pandemic event. This test will equip DHS with a novel response to help guide timely and appropriate treatment. The rapid assay is innovative in its ability to accurately confirm and differentiate a viral infection from a bacterial infection using a finger stick of blood.

About RPS

Founded in 2004, Rapid Pathogen Screening, Inc. (RPS®) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company's innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. For more information on RPS or its products, visit RPSdetectors.com.

SOURCE Rapid Pathogen Screening, Inc.